Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,514.37 65.12 0.40%
S&P 500 1,879.55 7.66 0.41%
NASDAQ 4,161.46 39.91 0.97%
Ticker Volume Price Price Delta
STOXX 50 3,196.70 -2.99 -0.09%
FTSE 100 6,687.06 5.30 0.08%
DAX 9,592.92 -7.17 -0.07%
Ticker Volume Price Price Delta
NIKKEI 14,546.27 157.50 1.09%
TOPIX 1,173.81 11.31 0.97%
HANG SENG 22,509.64 -221.04 -0.97%

Catalyst Pharmaceutical Partners Prices Registered Direct Public Offering



Catalyst Pharmaceutical Partners Prices Registered Direct Public Offering

CORAL GABLES, Fla., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical
Partners, Inc. (Nasdaq:CPRX) announced today that it has entered into
definitive agreements to sell 8.8 million shares of its common stock in a
registered direct public offering. The offering price for each share of common
stock is $1.72, resulting in gross proceeds of approximately $15.1 million.

The closing of this offering is expected to take place on or about September
10, 2013, subject to satisfaction of customary closing conditions. Catalyst
expects to use the net proceeds from this offering to fund costs associated
with the Company's product development efforts for Firdapse™, and for general
corporate purposes. Roth Capital Partners has acted as the exclusive placement
agent for the transaction. Further, Aegis Capital Corp., Maxim Group LLC and
H.C. Wainwright & Co. have acted as financial advisers with respect to this
offering.

The shares are being offered pursuant to a shelf registration statement on
Form S-3 (File No. 333-170945) filed pursuant to the Securities Act of 1933,
as amended, which was previously filed with, and declared effective by, the
Securities and Exchange Commission (SEC). A prospectus supplement relating to
the offering will be filed with the SEC and will be available on the SEC's
website at http://www.sec.gov.

This press release does not and shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. Copies of the prospectus
supplement and the accompanying base prospectus may be obtained, when
available, from Roth Capital Partners, LLC, 888 San Clemente Drive, Newport
Beach, CA 92660, (800) 678-9147 or by accessing the SEC's website,
http://www.sec.gov.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company
focused on the development and commercialization of novel prescription drugs
targeting rare (orphan) neuromuscular and neurological diseases, including
Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette
Syndrome. Catalyst's lead candidate, Firdapse™ for the treatment of LEMS, is
currently undergoing testing in a global, multi-center, pivotal phase III
trial. Catalyst is also developing a potentially safer and more potent
vigabatrin analog (designated CPP-115) to treat infantile spasms, and
epilepsy, as well as other neurological conditions associated with reduced
GABAergic signaling, like post-traumatic stress disorder and Tourette
Syndrome.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties, which may cause
Catalyst's actual results in future periods to differ materially from
forecasted results. A number of factors, including the timing of completion of
Catalyst's currently ongoing Phase III trial of Firdapse™, whether the Phase
III trial will be successful, whether the receipt of breakthrough therapy
designation for Firdapse™ will expedite the development and review of
Firdapse™ by the FDA or the likelihood that the product will be found to be
safe and effective, whether an NDA for Firdapse™ will ever be accepted for
filing by the FDA, the timing of any such NDA filing or acceptance, whether
any of Catalyst's product candidates will ever be approved for
commercialization or successfully commercialized, and those other factors
described in Catalyst's Annual Report on Form 10-K for the fiscal year 2012
and other filings with the U.S. Securities and Exchange Commission (SEC),
could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are
available from the SEC, may be found on Catalyst's website or may be obtained
upon request from Catalyst. Catalyst does not undertake any obligation to
update the information contained herein, which speaks only as of this date.

CONTACT: For Further Information Contact:
         Patrick J. McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         (305) 529-2522
         pmcenany@catalystpharma.com
        
         Melody Carey
         Rx Communications Group
         Co-President
         (917) 322-2571
         mcarey@rxir.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement